JP2015524808A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524808A5
JP2015524808A5 JP2015524450A JP2015524450A JP2015524808A5 JP 2015524808 A5 JP2015524808 A5 JP 2015524808A5 JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524450 A JP2015524450 A JP 2015524450A JP 2015524808 A5 JP2015524808 A5 JP 2015524808A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
apolipoprotein
administered
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015524450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524808A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/052078 external-priority patent/WO2014018763A2/en
Publication of JP2015524808A publication Critical patent/JP2015524808A/ja
Publication of JP2015524808A5 publication Critical patent/JP2015524808A5/ja
Pending legal-status Critical Current

Links

JP2015524450A 2012-07-25 2013-07-25 アポリポタンパク質aivを用いたi型糖尿病の治療法 Pending JP2015524808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675659P 2012-07-25 2012-07-25
US61/675,659 2012-07-25
PCT/US2013/052078 WO2014018763A2 (en) 2012-07-25 2013-07-25 Method of treating type i diabetes using apolipoprotein aiv

Publications (2)

Publication Number Publication Date
JP2015524808A JP2015524808A (ja) 2015-08-27
JP2015524808A5 true JP2015524808A5 (https=) 2016-08-25

Family

ID=48916270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015524450A Pending JP2015524808A (ja) 2012-07-25 2013-07-25 アポリポタンパク質aivを用いたi型糖尿病の治療法

Country Status (6)

Country Link
US (1) US9730980B2 (https=)
EP (1) EP2877197A2 (https=)
JP (1) JP2015524808A (https=)
AU (1) AU2013295721B2 (https=)
CA (1) CA2878695A1 (https=)
WO (1) WO2014018763A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140071272A (ko) 2011-01-19 2014-06-11 유니버시티 오브 신시내티 항 당뇨병 펩타이드로서의 아포리포프로테인 aiv
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
WO1994027629A1 (en) 1993-05-28 1994-12-08 Merck & Co., Inc. Method to control appetite and treat obesity
EP1436392A2 (en) * 2001-07-26 2004-07-14 Genset S.A. Gmg-2 polynucleotides and polypeptides and uses thereof
JP4423038B2 (ja) * 2001-10-05 2010-03-03 セローノ ジェネティクス インスティテュート ソシエテ アノニム Gzipポリヌクレオチドおよびポリペプチドならびにその使用
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
AU2005219876A1 (en) * 2004-03-01 2005-09-15 Peptimmune, Inc. Methods and compositions for treatment of autoimmune diseases
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
CA2719001A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103833713B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iii型、其制法和其药物组合物与用途
MY180661A (en) * 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
KR20140071272A (ko) * 2011-01-19 2014-06-11 유니버시티 오브 신시내티 항 당뇨병 펩타이드로서의 아포리포프로테인 aiv
AU2012366182B2 (en) * 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Similar Documents

Publication Publication Date Title
JP2011241213A5 (https=)
JP2013507439A5 (https=)
JP2016539921A5 (https=)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
JP2014521684A5 (https=)
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
JP2016514132A5 (https=)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
JP2011526886A5 (https=)
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2015517488A5 (https=)
JP2011519364A5 (https=)
TR201815158T4 (tr) Selektif glukagon reseptör agonistleri olarak eksendin-4 deriveleri.
JP2013542247A5 (https=)
JP2015520188A5 (https=)
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2014504601A5 (https=)
JP2014532722A5 (https=)
RU2016114098A (ru) Новое производное аналога инсулина
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
JP2015514115A5 (https=)